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Abstract
Background: REX1/ZFP42 is a well-known embryonic stem cell (ESC) marker. However, the role of REX1, itself, is relatively
unknown because the function of REX1 has only been reported in the differentiation of ESCs via STAT signaling pathways.
Human mesenchymal stem cells (hMSCs) isolated from young tissues and cancer cells express REX1.
Methodology/Principal Finding: Human umbilical cord blood-derived MSCs (hUCB-MSCs) and adipose tissue-derived MSCs
(hAD-MSCs) strongly express REX1 and have a lower activation status of p38 MAPK, but bone marrow-derived MSCs (hBM-
MSCs) have weak REX1 expression and higher activation of p38 MAPK. These results indicated that REX1 expression in
hMSCs was positively correlated with proliferation rates but inversely correlated with the phosphorylation of p38 MAPK. In
hUCB-MSCs, the roles of REX1 and p38 MAPK were investigated, and a knockdown study was performed using a lentiviral
vector-based small hairpin RNA (shRNA). After REX1 knockdown, decreased cell proliferation was observed. In REX1
knocked-down hUCB-MSCs, the osteogenic differentiation ability deteriorated, but the adipogenic potential increased or
was similar to that observed in the controls. The phosphorylation of p38 MAPK in hUCB-MSCs significantly increased after
REX1 knockdown. After p38 MAPK inhibitor treatment, the cell growth in REX1 knocked-down hUCB-MSCs almost
recovered, and the suppressed expression levels of CDK2 and CCND1 were also restored. The expression of MKK3, an
upstream regulator of p38 MAPK, significantly increased in REX1 knocked-down hUCB-MSCs. The direct binding of REX1 to
the MKK3 gene was confirmed by a chromatin immunoprecipitation (ChIP) assay.
Conclusions/Significance: These findings showed that REX1 regulates the proliferation/differentiation of hMSCs through
the suppression of p38 MAPK signaling via the direct suppression of MKK3. Therefore, p38 MAPK and REX-1 status can
determine the cell fate of adult stem cells (ASCs). These results were the first to show the role of REX1 in the proliferation/
differentiation of ASCs.
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Introduction
Embryonic stem cells (ESCs) are pluripotent stem cells that can
self-renew and generate all the cell types of the body; however,
they are not able to generate the extra embryonic trophoblast
lineage [1]. The transcriptional regulatory network of ESCs that
maintains pluripotency is well-established. Takahashi and Yama-
naka reported critical transcription factors that are necessary for
the induction of pluripotency [2]. The core transcription factors,
including the Yamanaka factors, have been relatively well-defined
in ESCs [3,4]. OCT4 [5] and REX1 [6] are transcription factors
that are characteristic markers of pluripotent stem cells. Paradox-
ically, over- or under-expression of Oct4 leads to the down-
regulation of Rex1 expression. Down-regulation of Oct4 and Rex1
triggers trophectoderm differentiation, while their up-regulation
triggers primitive endoderm and mesoderm differentiation [7].
Rex1 (Zfp42) was first identified as a gene that is transcriptionally
repressed by retinoic acid and encodes a zinc finger transcription
factor that is expressed at high levels in F9 teratocarcinoma stem
cells, embryonic stem cells, and other stem cells [8–10]. REX1 is a
member of the YY1 sub-family of transcription factors that can
function as repressors, activators or transcription initiators
depending on the sequence context of the YY1-binding sites with
respect to other regulatory elements [9,11]. Currently, REX1 is
widely used as a stem cell marker, and Rex1 inhibits signaling via
the Janus kinase (JAK)/STAT3 pathway during the differentiation
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mice show defects in the induction of a subset of marker genes in
the visceral endoderm, which suggests that Rex1 plays a role in
ESC differentiation [13].
The family of Mitogen-Activated Protein Kinases (MAPKs)
controls an enormous number of processes such as gene
expression, metabolism, cell proliferation, division, differentiation,
apoptosis and embryogenesis [14,15]. Five different MAPK
pathways have been described: the extracellular signal-regulated
kinases (ERKs), the stress-activated protein kinases (SAPKs), the c-
Jun N-terminal kinases (JNK), the ERK5/big MAP kinase 1
(BMK 1) and the p38 MAPK. The p38 MAPK pathway was
initially described as being activated by different types of cellular
stresses and cytokines. Numerous studies have reported the
involvement of p38 MAPK pathways in the regulation of a wide
spectrum of cellular processes including cell cycle arrest, apoptosis,
senescence, regulation of RNA splicing, tumorigenesis and the
growth/differentiation of specific cell types [16,17]. In mammals,
there are four p38 MAPKs: p38a, p38b, p38c (SAPK3, ERK6)
and p38d (SAPK4). MAP kinase p38a is ubiquitously expressed
whereas p38b, p38c and p38d have restricted expression patterns
[18]. Two major MAPK kinases (MKKs), MKK3 and MKK6, are
known to activate p38 MAPKs. MKK6 activates all four p38
MAPKs and MKK3 activates p38a, p38c and p38d [17,19].
Mesenchymal stem cells (MSCs) are promising tools in the field
of regenerative medicine. MSCs have been isolated from bone
marrow, adipose tissue, peripheral blood, fetal liver, lung, amniotic
fluid, chorionic villi of the placenta and umbilical cord blood
[20–25]. However, their ability to proliferate and differentiate
differs depending on their parental tissue type and subsequent
culture conditions. Roch et al. [26] described that OCT4, REX1
and GATA4 expression in human MSCs increases the differen-
tiation efficiency of these cells. Furthermore, first-trimester human
fetal MSCs express OCT4, NANOG and REX1 [27]; therefore,
hMSCs originating from young tissue have a strong potential to
obtain powerful multipotency and become large cell populations.
In addition to the isolation method, the culturing method is
another challenge in stem cell biology. Inhibition of p38 MAPK
facilitates ex vivo expansion of skin epithelial progenitor cells [28],
and several types of p38 MAPK inhibitors have been reported in
the literature. In this report, we determined that the phosphor-
ylation status of p38 MAPK and the expression of REX1 in
hMSCs was an important regulatory machine that maintains
ASCs via the direct regulation of MKK3.
Materials and Methods
Isolation of hMSCs, Cell Culture and Ethics Statement
Human umbilical cord blood-derived MSCs (hUCB-MSCs)
[29], human bone marrow derived MSCs (hBM-MSCs) [30] and
human adipose tissue-derived MSCs (hAD-MSCs) [31] were
isolated and cultured as previously described. In brief, two clones
of hAD-MSCs were isolated from freshly excised mammary fat
tissue acquired from the Ba-Ram plastic surgery hospital. Tissues
were obtained from 20 to 30 year-old women during reduction
mammoplasty. The hAD-MSCs were maintained in K-SFM
medium supplemented with 2 mM N-acetyl-L-cysteine (Sigma-
Aldrich, St. Louis, MO, USA) and L-ascorbic acid (0.2 mM,
Sigma-Aldrich). hBM-MSCs were isolated from three healthy
donors and were cultured in low glucose Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) without any additional growth factors. hUCB-MSCs
were obtained from umbilical cord blood immediately after full
term delivery with written consent from 20 to 30 year-old mothers
and the approval of the Boramae Hospital Institutional Review
Board (IRB). Three hUCB-MSC clones were used in this
experiment. The hUCB-MSCs were maintained in DMEM
(Invitrogen, Carlsbad, USA) containing 10% FBS. The passages
(p) of hMSCs used for the experiments were p5 in hUCB-MSCs,
p5 in hAD-MSCs and p3 in hBM-MSCs. The isolation and
research use of hAD-MSCs and hBM-MSCs were also approved
by the Boramae Hospital IRB with written consent. All procedures
were approved by the institutional review board of Seoul National
University (UCB-MSC, #0603/001-002; AD-MSC, #0600/001-
001; BM-MSC, #0910/001-003).
Cell proliferation and cell cycle analyses
To measure cell growth, CCK-8 (Dojindo Molecular Technol-
ogies Inc., San Diego, CA, USA) was used according to the
manufacturer’s protocol, and cells were measured at a wavelength
of 540 nm in an enzyme-linked immunosorbent assay plate reader
(EL800, Bio-Tek Instruments Inc., Winooski, VT, USA).
The stages of the cell cycle were detected by FACS analysis.
Briefly, the cells were washed twice with PBS and harvested by
trypsinization after 3 days. The cells were then washed again with
PBS and fixed with 70% ethanol at 220uC for 1 day. The fixed
cells were washed with ice cold PBS and stained with 50 mg/ml of
propidium iodide (Sigma, St Louis, Missouri, USA) in the presence
of 100 mg/ml RNase A (Sigma) for 30 minutes. The cell cycle
stages were analyzed using the FACS Calibur (Becton &
Dickinson, NJ, USA).
The construction and production of lentiviral vectors
Lentiviruses were generated using ViraPower
TM Lentiviral
packaging Mix (Invitrogen, Carlsbad, CA, USA). Lipofectamine
2000 (Invitrogen) was used for the transfection of 293FT cells
(Invitrogen) with SHDNAC-TRCN0000107810 (REX1 knock-
down-2, R2), SHDNAC-TRCN0000107812 (REX1 knockdown-
4, R4) and SHC002 (VC, random sequence inserted) (Sigma,
Saint Louis, MO, USA). Cell culture media was changed the day
after transfection and the supernatant was harvested at 48 and
72 hours post transfection. The viral supernatant was filtered using
0.4-mm pore filters (Invitrogen). Cells were transfected with REX-1
shRNA-producing lentivirus at MOI (multiplicity of infection) of
5–10. Polybrene (Sigma) was added to the cell culture media at a
final concentration of 6 mg/ml. The cell culture medium was
replaced with fresh culture medium the day after transfection. For
selection, puromycin was added to the cell culture media at a final
concentration of 3 mg/ml for 3 days.
RT-PCR and ChIP assay
Total RNA was extracted with an easy-spin
TM Total RNA
Extraction Kit (iNtRON Biotechnology, Sungnam, Korea)
according to the manufacturer’s instructions. Synthesis of cDNA
was carried out using the SuperScriptH III First-Strand Synthesis
System for RT-PCR (Invitrogen) with 1 mg total RNA and oligo
dT primers. The primers for each gene are shown in Table S1.
Gene expression was also analyzed using real-time PCR with
SYBR Green Master Mix reagents (Applied Biosystems, Foster
City, CA, USA). The expression level of REX-1 was detected, and
the real-time PCR values for gene expression were normalized to
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expres-
sion. Real time RT-PCR was performed with a LightCycler 480
Real-Time PCR System (Roche, Indianapolis, IN, USA). The
chromatin immunoprecipitation (ChIP) assay was carried out
according to the manufacturer’s protocol (cat#17-295, Upstate
Biotechnology, Billerica, MA, USA). PCR primers for the ChIP
assay are listed in Table S1.
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PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10493Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde for 20 minutes at
room temperature, and incubated with blocking solution (10%
normal goat serum, Rockland Immunochemicals, Gilbertsville,
PA, USA) overnight at 4uC. The cells were then incubated
overnight at 4uC with REX-1 primary antibody diluted in
blocking solution (ab50828, Abcam, Cambridge, MA, USA),
following which the cells were treated with the Alexa Fluor anti-
rabbit IgG secondary antibody (Invitrogen) for 1 hour. For nuclear
counter-staining, Hoechst 33238 (1 mg/ml, Sigma) was diluted to
1:500 in PBS and incubated with the cells for 15 minutes. Images
were captured with a confocal microscope (Eclipse TE200, Nikon,
Tokyo, Japan).
Western blotting
Cells were lysed with PRO-PREP (#17081, iNtRON Biotech-
nology). The cell lysates were then incubated on ice for 20 minutes
followed by centrifugation (13,000 rpm, 15 minutes, 4uC) and
supernatant collection. The protein concentrations of samples
were determined using the Protein Assay Reagent (Bio-Rad
laboratories, Hercules, CA, USA) according to the manufacturer’s
instructions. The protein samples (10–15 mg) were electrophoresed
using a 10–12% SDS-polyacrylamide electrophoresis gel. The
proteins were detected with primary antibodies that recognize
REX1 (ab50828, Abcam), CDK2 (#2546, Cell signaling Inc,
Danvers, MA, USA), CDK4 (#2906, Cell signaling Inc), Cyclin
B1 (#4138, Cell signaling Inc), Cyclin D1 (#2926, Cell signaling
Inc), p21 (sc-32, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), BAX (sc-493, Santa Cruz Biotechnology), pERK1/2
(V803A, Promega, Madison, WI, USA), ERK1/2 (V114A,
Promega), pGSK3b (#9336, Cell signaling Inc), GSK3b
(#9315, Cell signaling Inc), pSTAT3 (#9131, Cell signaling
Inc), STAT3 (#9139, Cell signaling Inc), STAT5 (sc-835, Santa
Cruz Biotechnology), MEK1/2 (#9122, Cell signaling Inc),
pMEK1/2 (#9121, Cell signaling Inc), NF-kB( #3034, Cell
signaling Inc), HES1 (AB5702, Chemicon), Pp38 (#4631, Cell
signaling Inc), p38 (#9212, Cell signaling Inc), MKK3 (#9232,
Cell signaling Inc) and GAPDH (MAB374, Chemicon). Antibody
recognition was detected with the respective secondary antibody
linked to horseradish peroxidase (Zymed Laboratories Inc., South
San Francisco, CA, USA). Secondary horseradish peroxidase–
conjugated antibodies were detected by enhanced chemilumines-
cence (ImageQuant 400, GE Healthcare, Piscataway, NJ, USA).
The relative quantities of each protein band, normalized to control
cells, were quantified using Quantity One software (version 4.6.5,
Bio-Rad Inc, Hercules, CA, USA).
ANNEXIN V staining for apoptosis
The apoptosis assay was performed with a two-color analysis of
FITC-labeled ANNEXIN V binding and propidium iodide (PI)
uptake using the ANNEXIN V–FITC Apoptosis Detection kit
following the manufacturer’s instructions (Calbiochem, San Diego,
CA, USA). Positioning of quadrants on ANNEXIN V/PI dot plots
was performed, and live cells (ANNEXIN V
–/PI
–), early/primary
apoptotic cells (ANNEXIN V
+/PI
–), late/secondary apoptotic cells
(ANNEXIN V
+/PI
+), and necrotic cells (ANNEXIN V
–/PI
+) were
distinguished.
Statistical analysis
The data are presented as mean value 6 standard deviation
obtained from three independent experiments in which hMSCs
clones originated from three individuals. The student’s t-test
(Microsoft Excel) was used for statistical analysis. Data are
considered statistically significant when p,0.01.
Figure 1. The expression levels of REX1, p38 MAPK and the cell proliferation of hMSCs. (A) The expression of REX1 in hUCB-MSCs, hAD-
MSCs and hBM-MSCs. hUCB-MSCs and hAD-MSCs have strong REX1 expression, but hBM-MSCs have very weak REX1 expression. (B) The expression of
p38 and phosphorylated p38 (Pp38) in hUCB-MSCs, hAD-MSCs and hBM-MSCs. The expression level of p38 was similar in the three types of hMSCs
examined. hBM-MSCs have the strongest expression level of Pp38 among the three types of hMSCs. (C) Cell proliferation measured by CCK-8. The
growth of hBM-MSCs was slowest among the three types of hMSCs. (D) REX1 primarily localized in the nucleus of hUCB-MSCs. Scale bars represent
100 mm. Error bars represent the standard deviation from three independent experiments.
doi:10.1371/journal.pone.0010493.g001
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The expression of REX1 is negatively correlated with the
phosphorylation of p38 MAPK in hMSCs
REX1 is expressed in ESCs and MSCs. Among three well-
characterized hMSCs, REX1 is strongly expressed in hUCB-
MSCs and hAD-MSCs; however, REX1 is weakly expressed in
hBM-MSCs when grown under previously reported culture
conditions [29–31]. In hUCB-MSCs, REX1 expression was
nearly five-fold greater than in hBM-MSCs (Fig. 1A). However,
in three types of hMSCs, the levels of phosphorylated p38 MAPK
(Pp38) was in inverse proportion to the expression of REX1
(Fig. 1B). The level of Pp38 in hBM-MSCs was four-fold stronger
than the level in hUCB-MSCs. The expression level of p38, itself,
was similar between the three types of hMSCs (Fig. 1B). The cell
proliferation rates of these three types of hMSCs were quite
different. In repeated experiments, hUCB-MSCs and hAD-MSCs
grew faster than hBM-MSCs (Fig. 1C). Therefore, the prolifer-
ation rates of hMSCs positively correlate with the REX1
expression level but inversely correlate with the level of Pp38
expression. REX1 was expressed in the majority of hUCB-MSCs,
and the localization of REX1 was primarily confined to the
nucleus of hUCB-MSCs as shown by immunocytochemistry
(Fig. 1D).
Knockdown of REX1 resulted in growth retardation of
hUCB-MSCs
hUCB-MSCs grew faster than hBM-MSCs but at a similar pace
as hAD-MSCs in in vitro culture. The discrepancy in the
proliferation speed may be potentially due to the difference in
REX1 expression in the different cell types. Therefore, a REX1
knockdown experiment was performed in hUCB-MSCs, which
had the highest expression of REX1 among the three types of
hMSCs. Four different shRNA producing lentiviruses that target
different REX1-regions were used for the experiment. Two
lentiviruses construct, REX1-2 (R2) and REX1-4 (R4), showed
specific inhibition of REX1 after puromycin selection (Fig. 2A).
After REX1 knockdown, cell growth severely decreased in hUCB-
MSCs (Fig. 2B and 2C). For detailed analysis of cell cycle
progression, FACS analysis was performed with the hUCB-MSCs
(Fig. 2D). The composition of the G0/G1 phase significantly
increased and the composition of the S phase significantly
decreased in REX1 knocked-down hUCB-MSCs compared to
vehicle control-infected hUCB-MSCs. Western blot analysis of cell
cycle regulators was performed using vehicle control-infected and
REX1 knocked-down hUCB-MSCs. After REX1 knockdown, the
expression levels of CDK2, Cyclin B1, CDK4 and Cyclin D1
decreased compared to the levels of vehicle control-infected
hUCB-MSCs. However, the expression of p27 did not change
when REX1 was knocked-down in hUCB-MSCs compared to
vehicle control-infected hUCB-MSCs (Fig. 2E).
Phosphorylation of p38 MAPK significantly increased
following the knockdown of REX1 in hUCB-MSCs
Among the detected MAPKs in hUCB-MSCs, p38 MAPK
signaling significantly changed when REX1 was knocked-down.
The expression level of p38 MAPK did not increase after REX1
knockdown; however, the level of Pp38 increased by more than
fifty-fold after REX1 was knocked-down in hUCB-MSCs, which
was verified in multiple experiments (Fig. 3A). SB203580 and
SB202190 are potent inhibitors of the p38a and p38b isoforms,
respectively, and all p38 MAPK isoforms are inhibited by
BIRB796 [32]. The hUCB-MSCs express all four types of p38
isoforms (Fig. 3B); therefore, REX1 knocked-down hUCB-MSCs
were treated with BIRB796. After p38 MAPK inhibitor
treatment, the level of Pp38 in REX1 knocked-down hUCB-
MSCs was not different compared to vehicle control-infected
hUCB-MSCs (Fig. 3C and 3E). After BIRB796 treatment, the
cell proliferation defect of REX1 knocked-down hUCB-MSCs
recovered, and the proliferation rate was similar to the rate in
vehicle control-infected hUCB-MSCs (Fig. 3D). Similarly, in
hUCB-MSCs, 1 mMo r1 0mM BIRB796 treatment repressed the
phosphorylation of p38 MAPK (Fig. 3E). In REX1 knocked-
down hUCB-MSCs, the suppressed expression levels of CDK2
and CCND1 recovered after BIRB796 treatment (Fig. 3F). The
expression of p53 and hyper-phosphorylated RB (PpRB) did not
change in REX1 knocked-down cells (Fig. 3F). In hUCB-MSCs,
the expression levels of ERK1/2 and Mitogen-Activated Protein
Kinase Kinase 1/2 (MAP2K1/2 or MEK1/2) did not change
after the knockdown of REX1. The phosphorylation of MEK
(pMEK1/2) and NF-kB expression were not significantly
different after the knockdown of REX1 in hUCB-MSCs
compared to vehicle control-infected hUCB-MSCs (Fig. 3G).
REX1 inhibits signaling via the STAT pathway in F9 cells [12];
however, the expression of STAT5 did not significantly change
after REX1 knockdown in hUCB-MSCs. The expression levels of
STAT3 and phosphorylated STAT3 increased after REX1
knockdown without regard to p38 MAPK inhibitor treatment
(Fig. 3H). After REX1 knockdown in hUCB-MSCs, the
expression levels of the p38s did not significantly change
Figure 2. REX1 knockdown resulted in the growth retardation
of hUCB-MSCs. (A) The expression of REX1 decreased after REX1-
knockdown lentivirus infection. (B) The cell proliferation of REX1
knocked-down hUCB-MSCs significantly decreased from two days after
infection. (C) The morphology of cells three days after culturing. REX1
knocked-down cells are not growing at a rate similar to the control cells.
(D) Cell cycle arrest was observed in REX1 knocked-down hUCB-MSCs
using FACS analysis. (E) The expression levels of Cyclins, CDK and cell
cycle inhibitors. The expression levels of CDK2, CCNB1, CDK4 and
CCND1 decreased, but p27 did not change after REX1 knockdown. Error
bars represent the standard deviation from three independent
experiments. *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0010493.g002
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treatment. (A) Significant phosphorylation of p38 MAPK (Pp38) was seen after REX1 knockdown in hUCB-MSCs. (B) hUCB-MSCs, hAD-MSCs and hBM-
MSCs express all four types of p38 isoforms. (C) After p38 MAPK inhibitor treatment (1 mM BIRB796), the phosphorylation of p38 MAPK was similar in
REX1 knocked-down hUCB-MSCs compared to vehicle control-infected hUCB-MSCs. (D) Cell proliferation was measured with CCK-8 for four days. The
cell proliferation of REX1 knocked-down hUCB-MSCs was similar with vehicle control-infected hUCB-MSCs after BIRB796 (1 mM) treatment. Without
BIRB796, the proliferation of REX1 knocked-down hUCB-MSCs significantly decreased compared with vehicle control-infected hUCB-MSCs. **, p,0.01.
(E) The p38 MAPK of REX1 knocked-down hUCB-MSCs was not activated after 1 mMo r1 0mM BIRB796 treatment compared to those of vehicle
control-infected hUCB-MSCs. (F) Changes in the expression of CDK and cell cycle inhibitors. The decreased expression of CDK2 and CCND1 recovered
after p38 MAPK inhibitor treatment. (G) The expression levels of ERK1/2, MEK, phospho-MEK (pMEK1/2) and NF-kB did not significantly change after
REX1 knockdown in hUCB-MSCs. (H) The expression changes of STAT3 and STAT5. The expression levels of STAT3 and phospho-STAT3 were
significantly increased after REX1 knockdown without regard to p38 MAPK inhibitor treatment. STAT5 expression did not change after the
knockdown of REX1. (I) p38a and p38b were up-regulated but p38c was down-regulated after REX1 knockdown in hUCB-MSCs. (J) REX1 expression of
hUCB-MSCs did not change after BIRB796 (p38 MAPK inhibitor) treatment. Error bars represent the standard deviation from three independent
experiments.
doi:10.1371/journal.pone.0010493.g003
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REX1 expression in hUCB-MSCs (Fig. 3J).
MKK3 expression significantly increased after REX1
knockdown
Inmammals,MKK3andMKK6arewellknownactivatorsofp38
MAPK via the phosphorylation of p38 MAPK [33]. The expression
of MKK6 did not significantly change after the knockdown of REX1,
but the expression of MKK3 dramatically increased in REX1
knocked-down hUCB-MSCs (Fig. 4A). The MKK3 RNA level
increased approximately seven-fold as confirmed by real-time RT-
PCR. The level of MKK3 protein expression also increased 3.4-fold
( F i g .4 B ) .I nh M S C s ,t h ee x p r e s s i o no fMKK3 was in inverse
proportion to REX1 expression (Figs. 1A and 4C). The expression
level of MKK3 in hUCB-MSCs was 20-fold less than the level in
hBM-MSCs. Therefore, the direct regulation of MKK3 by REX1 was
investigated. The human genomic DNA sequences of MKK3 were
analyzed for the presence of the REX1 binding motif. The DNA
binding motif of REX1 contains the core sequences of GCAGCCAT
or GCCATTA [34]. In human genomic DNA, only three positions
in MKK3 contain consensus sequences for REX1 binding. These
consensus sequences are located 1 Kb upstream of the first exon
(Promoter region), inside of the first exon (Exon 1) and inside of the
first intron (Intron 1) (Fig. 4D). A ChIP assay was performed to
confirm the direct binding of REX1 to MKK3, and REX1specifically
bindsonly to the first exonof MKK3 (Fig.4D).OtherregionsofMKK3
did not contain REX1 binding motifs or a positive signal from the
ChIP assay.
Alterations in the differentiation ability, and NOTCH and
WNT signaling, of hUCB-MSCs following REX1
knockdown
The differentiation ability of hUCB-MSCs was investigated
after the knockdown of REX1. The adipogenic potentiality in
REX1 knocked-down hUCB-MSCs slightly increased or was
similar to vehicle control-infected hUCB-MSCs after adipogenic
differentiation as shown by Oil Red O staining. However, the
osteogenic differentiation potential of REX1 knocked-down
hUCB-MSCs visibly deteriorated after osteogenic induction as
shown by Alizarin Red S staining (Fig. 5A).
Notch signaling is important for the differentiation of MSCs
[35,36]. JAGGED1 (JAG1) is a ligand of the NOTCH receptor
and plays key roles in cell differentiation and morphogenesis [37].
The expression of JAG1 was up-regulated in REX1 knocked-down
hUCB-MSCs compared to vehicle control-infected hUCB-MSCs.
NOTCH proteins are single-pass trans-membrane receptors that
regulate cell fate decisions during development. The expression
levels of NOTCH1 and NOTCH4 also increased in REX1 knocked-
down hUCB-MSCs compared to vehicle control-infected hUCB-
MSCs (Fig. 5B). As a consequence, the expression of HES1, a
NOTCH target molecule, was up-regulated in REX1 knocked-
down hUCB-MSCs compared to vehicle control-infected hUCB-
MSCs (Fig. 5B).
Canonical WNT/b-CATENIN signaling also plays an impor-
tant role in regulating the differentiation of MSCs [38,39]. The
expression levels of b-CATENIN, GSK3-b and phospho-GSK3-
b at serine-9 decreased after REX1 inhibition in hUCB-MSCs
(Fig. 5C). The expression of a WNT signaling related gene,
AXIN1, was not significantly different in REX1 knocked-down
and vehicle control-infected hUCB-MSCs; however, the expres-
sion levels of FZD2, LRP5 and DKK1 decreased in REX1
knocked-down hUCB-MSCs compared to vehicle control-
infected hUCB-MSCs (Fig. 5D). The expression of ZNF281,a
core transcription factor in stem cells that functions during
hMSC osteogenesis (unpublished data), decreased in REX1
knocked-down hUCB-MSCs compared to the vehicle control-
infected hUCB-MSCs (Fig. 5E). The expression of c-MYC,
another core transcription factor of stem cells, did not change
significantly after REX1 knockdown in hUCB-MSCs. In order
to evaluate the changes in expression of other polycomb group
genes, the expression levels of two polycomb group genes that
are important to maintenance and specification of stem cells
[40], SUZ12 and BMI1, were measured. The expression levels of
SUZ12 and BMI1 decreased after REX1 knockdown in hUCB-
MSCs (Fig. 5E).
REX1 inhibition did not affect apoptosis of hUCB-MSCs
and Pp38 level was not significantly altered after REX1
knockdown in hBM-MSCs
Apoptosis is influenced by p38 MAPK, which is also important
to cell growth. ANNEXIN V is used as a probe in the ANNEXIN
V assay to detect cells that express phosphatidyl serine on the cell
Figure 4. The expression of MKK3/6 in REX1 knocked-down
hUCB-MSCs and normally cultured hMSCs, and the MKK3 ChIP
assay in hUCB-MSCs. (A) MKK3 expression significantly increased, but
MKK6 did not significantly change after REX1 knockdown as shown by
RT-PCR. (B) MKK3 increased after REX1 knockdown at the protein
expression level. (C) The expression level of MKK3 in hUCB-MSCs was 20-
fold less than the level in hBM-MSCs under normal culture conditions as
shown by real-time RT-PCR. (D) The ChIP assay for REX1. Three regions
have REX1 consensus sequences in the MKK3 genomic DNA. REX1 binds
to the first exon region (MKK3Exon1) of MKK3. Abbreviations:
MKK3Promt, MKK3 promoter region; MKK3Exon1, MKK3 exon 1 region;
MKK3Intron1, MKK3 intron 1 region. Error bars represent the standard
deviation from three independent experiments.
doi:10.1371/journal.pone.0010493.g004
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death [41,42]. ANNEXIN V staining was performed on three
hUCB-MSCs clones derived from three different individuals
(Fig. 6A). The number of apoptotic cells (Q2 and Q4 fraction)
or necrotic cells (Q1 fraction) of REX1 knocked-down hUCB-
MSCs did not significantly differ from the vehicle control-infected
hUCB-MSCs (Fig. 6B). The expression of BAX, a marker protein
of apoptosis, also did not increase in REX1 knocked-down hUCB-
MSCs compared to vehicle control-infected hUCB-MSCs
(Fig. 6C).
In hAD-MSCs, the level of Pp38 significantly increased after the
knockdown of REX1 similar to hUCB-MSCs. However, in hBM-
MSCs, the level of Pp38 increased slightly after REX1 knockdown
(Fig. 6D). Basically, in hBM-MSCs, REX1 expression was very
low (Fig. 1A). Also, under normal culture conditions, the intrinsic
Pp38 and MKK3 expression levels were much higher in hBM-
MSCs than in hUCB-MSCs or in hAD-MSCs (Figs. 1B, 4C and
6D). Therefore, the effect of the REX1 knockdown did not
significantly influence Pp38 level in hBM-MSCs compared to
other types of hMSCs.
Discussion
The p38 MAPK is important for cell growth, apoptosis and
differentiation in mammalian cells. Under specific culture
conditions, in hUCB-MSCs, which strongly express REX1, p38
MAPK is suppressed. However, hBM-MSCs, which have weak
REX1 expression, have activated p38 MAPK and a high
expression level of MKK3 under normal culture conditions.
REX1 expression was inversely correlated with p38 MAPK
activation and positively correlated with the proliferation rates of
the three types of hMSCs examined.
REX1, a pluripotent marker gene, was expressed in some types
of hMSCs and cancer cells as well as ESCs. In hUCB-MSCs, the
knockdown of REX1 resulted in severe growth retardation. The
functions of p38a have been previously reported and p38a is a
major component of p38 MAPK in the majority of cells. p38a can
negatively regulate cell cycle progression at both the G1/S and
G2/M transitions by several mechanisms such as, the down-
regulation of Cyclins and the up-regulation of CDK inhibitors
[43]. In REX1 knocked-down hUCB-MSCs, the cell cycle was
Figure 5. Differentiation study, NOTCH and WNT expression changes in REX1 knocked-down hUCB-MSCs. (A) After a three week
induction, adipogenic and osteogenic differentiated hUCB-MSCs were stained with Oil Red O or Alizarin Red S. The number of adipogenic
differentiated cells was similar to vehicle control-infected hUCB-MSCs or was slightly increased in REX1 knocked-down hUCB-MSCs. Osteogenesis of
REX1 knocked-down hUCB-MSCs decreased compared to vehicle control-infected hUCB-MSCs. (B) The expression changes of NOTCH signaling genes
after REX1 knockdown. The expression levels of JAG1, NOTCH1 and NOTCH4 increased after REX1 knockdown. HES1 expression increased 1.2-fold after
REX1 knockdown. (C) The expression levels of GSK3-b, phospho-GSK3-b at serine-9 (pGSK3b) and b-CATENIN decreased after REX1 knock-down in
hUCB-MSCs. (D) The expression levels of FZD2, LRP5 and DKK1 decreased after REX1 knockdown in hUCB-MSCs. (E) The expression levels of core
transcription factors and polycomb group genes. The expression level of ZNF281 was down-regulated after REX1 knockdown in hUCB-MSCs. The
expression levels of SUZ12 and BMI1 also decreased after REX1 knockdown. The expression of c-MYC did not change after REX1 knockdown.
Abbreviations: Adipo, adipogenic induction; Osteo, osteogenic induction. Error bars represent the standard deviation from three independent
experiments. Scale bars represent 100 mm.
doi:10.1371/journal.pone.0010493.g005
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control-infected hUCB-MSCs. Passage through the cell cycle
requires the successive activation of different cyclin-dependent
protein kinases (CDKs) and Cyclins [44,45]. Cyclin E, in
association with CDK2, is required for the G1/S transition
[46,47]. Both Cyclin A and the B-type Cyclins associate with
CDC2 to promote entry into mitosis [48]. The expression levels of
CDK2, CCND1 and Cyclin B1 decreased in REX1 knocked-
down hUCB-MSCs compared with the levels in vehicle control-
infected hUCB-MSCs. The expression levels of CDK2 and
CCND1 recovered after p38 MAPK inhibitor treatment in
REX1 knocked-down hUCB-MSCs. However, the expression
levels of CDK inhibitors, p53 and PpRB, did not change after p38
MAPK inhibitor treatment or REX1 knock-down in hUCB-
MSCs. Although p38 MAPK was highly activated in REX1
knocked-down hUCB-MSCs, the cells grew slowly. Notch
signaling, which increased in REX1 knocked-down hUCB-MSCs,
also regulates stem cell number and has an opposite role of p38
MAPK [49]. Therefore, in REX1 knocked-down hUCB-MSCs,
the growth inhibition signal by activated p38 MAPK was partially
compensated by the cell proliferation signals from NOTCH
activation.
Activation of p38 MAPK also contributes to chemically-induced
cell death [50]. The possibility of increasing apoptosis in REX1
Figure 6. Apoptosis after REX1 knockdown in hUCB-MSCs and REX1 inhibition in hMSCs and the summary of the role of REX1 in
stem cells. (A, B) Apoptotic cell death was not significantly different in REX1 knocked-down and vehicle control-infected hUCB-MSCs. (C) The
expression of BAX did not change after REX1 knockdown in hUCB-MSCs. (D) Significant activation of p38 MAPK was observed after REX1 knockdown
in hUCB-MSCs and hAD-MSCs but only slightly increased in hBM-MSCs. hBM-MSCs, which have low expression of REX1, have highly activated p38
MAPK (Pp38) in vehicle control-infected cells. (E) REX1 suppresses MKK3 expression, which activates p38 MAPK. REX1 also suppresses STAT3
expression and NOTCH signals. Error bars represent the standard deviation from three independent experiments.
doi:10.1371/journal.pone.0010493.g006
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the ANNEXIN V assay showed no significant difference between
REX1 knocked-down and vehicle control-infected hUCB-MSCs.
In addition, the expression of STAT3 increased in REX1
knocked-down hUCB-MSCs, which was also previously reported
[12]. After p38 MAPK inhibitor treatment and REX1 knock-
down, the STAT3 activation patterns did not change, suggesting
that STAT3 suppression by REX1 is independent of p38 MAPK
signaling.
Activation of p38 MAPK is important for the differentiation of
mouse ESCs [51] and hMSCs [52]. The known up-stream
regulators of p38 MAPK are MKK3 and MKK6, which are
activated in response to many types of cell stresses [53,54].
However, in stem cells, the transcriptional regulation of MKK3 and
MKK6 was not previously reported. REX1 expression is specific to
pluripotent stem cells, several types of hMSCs and cancer cells.
REX1 is highly expressed in hUCB-MSCs, but MKK3 expression
is approximately 20-fold lower in hUCB-MSCs, compared to
hBM-MSCs, where REX1 expression is low under normal culture
conditions. REX1 suppresses the expression of MKK3 in hMSCs,
which was mediated by REX1 binding directly to the first exon of
MKK3 (Fig. 6E).
The Notch signaling pathway is implicated in the differentiation
[55,56] and the immune-modulation of MSCs [57]. Notch
signaling inhibits chondrogenesis of hMSCs [35]. Also, the
expression of the NOTCH ligand and its receptors (JAG1,
NOTCH1 and NOTCH 4) increased after the knockdown of
REX1 in hUCB-MSCs. Therefore, osteogenic differentiation
deformity was partially caused by NOTCH activation after
REX1 knockdown in hUCB-MSCs. Notch signaling also has a
role in adipogenesis, and in 3T3-L1 cells, the reduction of Hes-1
inhibits adipogenic differentiation [58]. The activation of p38
MAPK activates C/EBPb, a transcription factor that has a critical
role in adipogenesis [59]. Therefore, after REX1 knockdown in
hUCB-MSCs, increased adipogenesis was potentially caused by
both NOTCH and p38 MAPK activation. The expression level of
HES1, a target molecule of NOTCH signaling, increased in
REX1 knocked-down hUCB-MSCs; therefore, REX1 may
suppress the NOTCH signaling pathways and maintains the
undifferentiated state of hUCB-MSCs (Fig. 6E).
In MSCs, Wnt/b-catenin (i.e., canonical) signaling is also
important to maintain stemness and multipotency [60–62]. b-
CATENIN decreased after REX1 knockdown in hUCB-MSCs.
The function of GSK3-b, which inactivates b-CATENIN, is
inhibited by the phosphorylation of serine-9 [63]. In REX1
knocked-down hUCB-MSCs, the expression level of GSK3-b
decreased, and the level of phosphorylated GSK3-b at serine-9
also decreased. p38 MAPK down-regulates WNT/b-CATENIN
signaling via GSK3-b [64], which was confirmed by our results.
Notch 1 over-expression inhibits osteoblastogenesis by suppressing
Wnt/b-Catenin signaling [65], which correlated with osteogenic
deformity in REX1 knocked-down hUCB-MSCs. The increased
NOTCH signal also caused the suppression of WNT in REX1
knocked-down hUCB-MSCs. Several core transcription factors
that have critical roles in ESCs were expressed in hUCB-MSCs.
The effect of REX1 knockdown on these transcription factors was
different in each gene expression. The expression of ZNF281
decreased in REX1 knocked-down hUCB-MSCs compared to
vehicle control-infected hUCB-MSCs, but the expression of c-
MYC did not change when REX1 was knocked-down in hUCB-
MSCs. REX1 is considered to be a member of the YY1 gene
family which is a polycomb group gene. The expression levels of
the polycomb group genes, SUZ12 and BMI1, were reduced in
REX1 knocked-down hUCB-MSCs. Therefore, REX1 also has a
role in modulating the chromatin structure of hUCB-MSCs, which
needs to be further explored.
In conclusion, REX1 represses the expression of MKK3, which
can activate p38 MAPK in hMSCs. The high expression level of
REX1 in stem cells protects cell differentiation by suppressing p38
MAPK activation via MKK3 suppression and by suppressing
NOTCH and STAT3 signaling. ASCs that highly express REX1
have more prominent cell-proliferation ability and multipotency
than low REX1-expressing ASCs due to the p38 MAPK
suppression in stem cells. Therefore, REX1 is a proper marker
not only in ESCs but also in highly efficient multipotent human
ASCs. Overall, the suppression of p38 MAPK is useful in the
collection and culturing of multipotent human ASCs that do not
have sufficient expression levels of REX1. This will be beneficial to
the field of regenerative medicine.
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